Rhythm Awarded $1.35M From Michael J. Fox Foundation

NewsGuard 100/100 Score

The Michael J. Fox Foundation for Parkinson's Research (MJFF) gave Rhythm a $1.35 million research grant to help fund a Phase II trial of RM-131, the company's ghrelin agonist, for the treatment of refractory constipation in patients with Parkinson's disease. The study expands an ongoing Phase II program for RM-131 for the treatment of both upper and lower gastrointestinal (GI) functional disorders which Rhythm initiated earlier this year.

The MJFF-funded trial will assess the efficacy and safety of RM-131 administered daily for two weeks. Approximately 56 patients are expected to be enrolled. Rhythm is conducting the study in partnership with the Parkinson's Study Group and Ronald Pfeiffer, M.D., University of Tennessee.

RM-131 is a small-peptide analog of ghrelin, a hormone produced in the stomach that stimulates gastrointestinal activity. Derived from the natural ghrelin sequence, RM-131 has been optimized to stimulate gastrointestinal motility, with greater potency and enhanced stability and pharmacokinetics, according to the company, which is also evaluating RM-131 for the treatment of diabetic gastroparesis in type 1 diabetic patients. In May, Rhythm reported that RM-131 significantly accelerates early gastric emptying and reduces upper GI symptoms in type 1 diabetic patients with diabetic gastroparesis.

In 2010, Rhythm obtained an exclusive license to Ipsen's ghrelin programs. As part of that agreement, Ipsen could receive payments of up to U.S. $80 million upon the achievement of certain milestones as well as royalties on future sales of the products. In addition, Ipsen acquired 17% equity in Rhythm.


Genetic Engineering & Biotechnology News (GEN) Genetic Engineering & Biotechnology News (GEN)This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Can virtual reality be the future of brain health? New research suggests VR exercise enhances working memory